Enrico Martin

285 General discussion and future perspectives References 1. Stucky C-CH, Johnson KN, Gray RJ, et al. Malignant peripheral nerve sheath tumors (MPNST): the Mayo Clinic experience. Ann Surg Oncol . 2012;19(3):878-885. doi:10.1245/s10434-011-1978-7 2. Zou C, Smith KD, Liu J, et al. Clinical, pathological, and molecular variables predictive of malignant peripheral nerve sheath tumor outcome. Ann Surg . 2009;249(6):1014-1022. doi:10.1097/ SLA.0b013e3181a77e9a 3. Anghileri M, Miceli R, Fiore M, et al. Malignant peripheral nerve sheath tumors: prognostic factors and survival in a series of patients treated at a single institution. Cancer . 2006;107(5):1065-1074. doi:10.1002/cncr.22098 4. Wasa J, Nishida Y, Tsukushi S, et al. MRI features in the differentiation of malignant peripheral ner ve sheath tumors and neurofibromas. Am J Roentgenol . 2010;194(6):1568-1574. doi:10.2214/ AJR.09.2724 5. Ferner RE. Neurofibromatosis 1. Eur J Hum Genet . 2007;15(2):131-138. doi:10.1038/ sj.ejhg.5201676 6. Brennan MF, Antonescu CR, Moraco N, Singer S. Lessons learned from the study of 10,000 patients with soft tissue sarcoma. Ann Surg . 2014;260(3):412-416. doi:10.1097/SLA.0000000000000869 7. Ferrari A, Miceli R, Rey A, et al. Non- metastatic unresected paediatric non- rhabdomyosarcoma soft tissue sarcomas: results of a pooled analysis from United States and European groups. Eur J Cancer . 2011;47(5):724-731. doi:10.1016/j. ejca.2010.11.013 8. Kahn J, Gillespie A, Tsokos M, et al. Radiation therapy in management of sporadic and neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors. Front Oncol . 2014;4:324. doi:10.3389/fonc.2014.00324 9. Ferrari A, Bisogno G, Carli M. Management of childhood malignant peripheral nerve sheath tumor. Paediatr Drugs . 2007;9(4):239-248. 10. Kaushal A, Citrin D. The role of radiation therapy in the management of sarcomas. Surg Clin North Am . 2008;88(3):629-646, viii. doi:10.1016/j.suc.2008.03.005 11. Sharif S, Ferner R, Birch JM, et al. Second primary tumors in neurofibromatosis 1 patients treated for optic glioma: substantial risks after radiotherapy. J Clin Oncol . 2006;24(16):2570-2575. doi:10.1200/JCO.2005.03.8349 12. Carli M, Ferrari A, Mattke A, et al. Pediatric malignant peripheral nerve sheath tumor: the Italian and German soft tissue sarcoma cooperative group. J Clin Oncol . 2005;23(33):8422-8430. doi:10.1200/ JCO.2005.01.4886 13. Gronchi A, Palmerini E, Quagliuolo V, et al. Neoadjuvant Chemotherapy in High- Risk Soft Tissue Sarcomas: Final Results of a Randomized Trial From Italian (ISG), Spanish (GEIS), French (FSG), and Polish (PSG) Sarcoma Groups. J Clin Oncol Off J Am Soc Clin Oncol . 2020;38(19):2178-2186. doi:10.1200/JCO.19.03289 14. Adjuvant chemotherapy for localised resec table sof t tissue sarcoma in adul t s. Cochrane database Sy s t R e v . 20 0 0 ; (4) : CD0 01419. doi:10.1002/14651858.CD001419 15. Pervaiz N, Colterjohn N, Farrokhyar F, Tozer R, Figueredo A, Ghert M. A systematic meta-analysis of randomized controlled trials of adjuvant chemotherapy for localized resectable soft-tissue sarcoma. Cancer . 2008;113(3):573-581. doi:10.1002/ cncr.23592 16. Gortzak E, Azzarelli A, Buesa J, et al. A randomised phase II study on neo- adjuvant chemotherapy for “high-risk” adult soft-tissue sarcoma. Eur J Cancer . 2001;37(9):1096-1103. 12